8.570EUR-2.61%Mkt Cap: 429.32M EURP/E: —Last update: 2026-06-01
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clini…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap429.32M EUR
Enterprise Value491.16M EUR
Revenue (TTM)65.43M EUR
Gross Profit65.13M EUR
Net Income (TTM)-85.97M EUR
Revenue/Share1.309 EUR
Last Price8.570 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)10.50
PEG—
EV/EBITDA-9.48
EV/Revenue7.51
P/S6.74
P/B-19.60
EPS (TTM)-1.72
EPS (Forward)0.84
52W Range
3.04883% of range9.715
52W High9.715 EUR
52W Low3.048 EUR
Profitability
Gross Margin99.54%
Oper. Margin-179.59%
EBITDA Margin-79.15%
Profit Margin-131.38%
ROE381.47%
ROA-54.05%
Growth
Revenue Growth211.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.24M EUR
CapEx (TTM)3.42M EUR
FCF Margin-86.99%
FCF Yield-13.26%
Net Debt49.59M EUR
Net Debt/EBITDA-0.96
Balance Sheet
Debt/Equity-6.69
Current Ratio2.00
Quick Ratio1.96
Book Value/Sh-0.4490 EUR
Cash/Share2.015 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)14.00 EUR
Target Range11.00 EUR – 15.00 EUR
# Analysts4
Ownership
Shares Out.50.10M
Float41.15M
Insiders13.22%
Institutions8.82%
Technical
SMA 508.558 (+0.1%)
SMA 2005.908 (+45.1%)
Beta1.08
S&P 52W Chg27.94%
Avg Vol (30d)186.76K
Avg Vol (10d)156.85K
Technical Indicators
RSI (14)56.1
MACD0.0468
MACD Signal0.0313
MACD Hist.+0.0155
BB Upper9.026 EUR
BB Middle8.582 EUR
BB Lower8.138 EUR
BB Width10.34%
ATR (14)0.4036 EUR
Vol Ratio (20d)2.02x